Index nr
|
Kemiskt namn
|
EG-nr
|
CAS-nr
|
Klassificering
|
Märkning
|
Särskilda koncentrationsgränser, M-faktorer och uppskattad akut toxicitet (ATE)
|
Anm.:
|
Faroklass och kategorikod(er)
|
Faroangivelsekod(er)
|
Faropiktogram, signalordskod(er)
|
Faroangivelsekod(er)
|
Kompl. faroangivelsekod(er)
|
”007-030-00-3
|
salpetersyra ...% [C ≤ 70 %]
|
231-714-2
|
7697-37-2
|
Ox. Liq. 3
Acute Tox. 3
Skin Corr. 1A
|
H272
H331
H314
|
GHS03
GHS06
GHS05
Dgr
|
H272
H331
H314
|
EUH071
|
Ox. Liq. 3; H272: C ≥ 65 %
inhalation: ATE = 2,65 mg/l (ångor)
Skin Corr. 1A; H314: C ≥ 20 %
Skin Corr. 1B; H314: 5 % ≤ C < 20 %
|
B”
|
”014-048-00-5
|
kiselkarbidfibrer (med diameter < 3 μm, längd > 5 μm och profilförhållande ≥ 3:1)
|
206-991-8
|
409-21-2
308076-74-6
|
Carc. 1B
|
H350i
|
GHS08
Dgr
|
H350i”
|
|
|
|
”014-049-00-0
|
trimetoxivinylsilan; trimetoxi(vinyl)silan
|
220-449-8
|
2768-02-7
|
Skin Sens. 1B
|
H317
|
GHS07
Wng
|
H317”
|
|
|
|
”014-050-00-6
|
tris(2-metoxietoxi)vinylsilan;
6-(2-metoxetoxi)-6-vinyl-2,5,7,10-tetraoxa-6-silaundekan
|
213-934-0
|
1067-53-4
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD”
|
|
|
|
”016-098-00-3
|
dimetyldisulfid
|
210-871-0
|
624-92-0
|
Flam. Liq. 2
Acute Tox. 3
Acute Tox. 3
STOT SE 3
STOT SE 1
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H225
H331
H301
H336
H370 (övre luftvägar, inhalation)
H319
H317
H400
H410
|
GHS02
GHS06
GHS08
GHS09
Dgr
|
H225
H331
H301
H336
H370 (övre luftvägar, inhalation)
H319
H317
H410
|
|
inhalation: ATE = 5 mg/l (ångor)
oral: ATE = 190 mg/kg bw
M = 1
M = 10”
|
|
”029-024-00-X
|
granulerad koppar;
[partikellängd: 0,9 mm–6,0 mm; partikelbredd: 0,494–0,949 mm]
|
231-159-6
|
7440-50-8
|
Aquatic Chronic 2
|
H411
|
GHS09
|
H411”
|
|
|
|
”029-025-00-5
|
bis(N-hydroxi-N-nitrosocyklohexylaminato-O,O’)koppar;
bis(N-cyklohexyl-diazenium-dioxi)-koppar
[Cu-HDO]
|
239-703-4
|
312600-89-8
15627-09-5
|
Flam. Sol. 1
Acute Tox. 4
STOT RE 2
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H228
H302
H373 (lever)
H318
H400
H410
|
GHS02
GHS07
GHS08
GHS05
GHS09
Dgr
|
H228
H302
H373 (lever)
H318
H410
|
|
oral: ATE = 360 mg/kg bw
M = 1
M = 1”
|
|
”050-031-00-9
|
dioktyltenndilaurat; [1]
dioktyltenndikokosacyloxi-derivat [2]
|
222-883-3 [1] 293-901-5 [2]
|
3648-18-8 [1] 91648-39-4 [2]
|
Repr. 1B
STOT RE 1
|
H360D
H372 (immunsystem)
|
GHS08
Dgr
|
H360D
H372 (immunsystem)”
|
|
|
|
”601-092-00-0
|
dibenso[def,p]krysen;
dibenso[a,l]pyren
|
205-886-4
|
191-30-0
|
Carc. 1B
Muta. 2
|
H350
H341
|
GHS08
Dgr
|
H350
H341
|
|
Carc. 1B; H350: C ≥ 0,001 %”
|
|
”603-237-00-3
|
ipkonazol (ISO);
(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-klorbensyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmetyl)cyklopentanol
|
–
|
125225-28-7
115850-69-6
115937-89-8
|
Repr. 1B
Acute Tox. 4
STOT RE 2
Aquatic Chronic 1
|
H360D
H302
H373 (ögon, hud, lever)
H410
|
GHS08
GHS07
GHS09
Dgr
|
H360D
H302
H373 (ögon, hud, lever)
H410
|
|
oral: ATE = 500 mg/kg bw
M = 100”
|
|
”603-238-00-9
|
bis(2-(2-metoxietoxi)etyl)eter; tetraglym; tetraetylenglykoldimetyleter; TEGDME
|
205-594-7
|
143-24-8
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD”
|
|
|
|
”603-239-00-4
|
paklobutrazol (ISO);
(2RS,3RS)-1-(4-klorfenyl)-4,4-dimetyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol
|
–
|
76738-62-0
|
Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H332
H302
H319
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H361d
H332
H302
H319
H410
|
|
inhalation: ATE = 3,13 mg/l (damm eller dimma)
oral: ATE = 490 mg/kg bw
M = 10
M = 10”
|
|
”603-240-00-X
|
2,2-bis(brommetyl)propan-1,3-diol
|
221-967-7
|
3296-90-0
|
Carc. 1B
Muta. 1B
|
H350
H340
|
GHS08
Dgr
|
H350
H340”
|
|
|
|
”603-241-00-5
|
geraniol;
(2E)-3,7-dimetylokta-2,6-dien-1-ol
|
203-377-1
|
106-24-1
|
Skin Sens. 1
|
H317
|
GHS07
Wng
|
H317”
|
|
|
|
”605-041-00-3
|
2-(4-tert-butylbensyl)propionaldehyd
|
201-289-8
|
80-54-6
|
Repr. 1B
|
H360Fd
|
GHS08
Dgr
|
H360Fd”
|
|
|
|
”607-738-00-8
|
MCPA-tioetyl (ISO);
S-etyl(4-klor-2-metylfenoxi)etantioat; S-etyl-4-klor-o-tolyloxitioacetat
|
246-831-4
|
25319-90-8
|
Acute Tox. 4
STOT RE 2
Aquatic Acute 1 Aquatic Chronic 1
|
H302
H373 (lever)
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H302
H373 (lever)
H410
|
|
oral: ATE = 450 mg/kg bw
M = 10
M = 10”
|
|
”607-740-00-9
|
diisooktylftalat
|
248-523-5
|
27554-26-3
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD”
|
|
|
|
”607-741-00-4
|
4-{[(6-klorpyridin-3-yl)metyl](2,2-difluoretyl)amino}furan-2(5H)-on; flupyradifuron
|
–
|
951659-40-8
|
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H373 (muskel)
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H302
H373 (muskel)
H410
|
|
oral: ATE = 500 mg/kg bw
M = 10
M = 10”
|
|
”607-742-00-X
|
tienkarbazonmetyl (ISO);
metyl-4-[(4,5-dihydro-3-metoxi-4-metyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-metyltiofen-3-karboxylat
|
–
|
317815-83-1
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 1 000
M = 1 000 ”
|
|
”607-743-00-5
|
L-(+)-mjölksyra;
(2S)-2-hydroxipropansyra
|
201-196-2
|
79-33-4
|
Skin Corr. 1C
Eye Dam. 1
|
H314
H318
|
GHS05
Dgr
|
H314
|
EUH071”
|
|
|
”607-744-00-0
|
2-metoxietylakrylat
|
221-499-3
|
3121-61-7
|
Flam. Liq. 3
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1
|
H226
H341
H360FD
H331
H302
H314
H318
H317
|
GHS02
GHS05
GHS06
GHS08
Dgr
|
H226
H341
H360FD
H331
H302
H314
H317
|
EUH071
|
inhalation: ATE = 2,7 mg/l (ångor)
oral: ATE = 404 mg/kg bw”
|
|
”607-745-00-6
|
glyoxylsyra …%
|
206-058-5
|
298-12-4
|
Eye Dam. 1
Skin Sens. 1B
|
H318
H317
|
GHS05
GHS07
Dgr
|
H318
H317
|
|
|
B”
|
”607-746-00-1
|
natrium-N-(hydroximetyl)glycinat;
[formaldehyd frisatt från natrium-N-(hydroximetyl)glycinat]
|
274-357-8
|
70161-44-3
|
Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
|
H350
H341
H332
H302
H335
H315
H319
H317
|
GHS08
GHS07
Dgr
|
H350
H341
H332
H302
H335
H315
H319
H317
|
|
inhalation: ATE = 3 mg/l (damm eller dimma)
oral: ATE = 1 000 mg/kg bw
|
8
9”
|
”611-181-00-6
|
kalium(oxido-NNO-azoxi)cyklohexan;
cyklohexylhydroxidiazen-1-oxid, kaliumsalt;
[K-HDO]
|
–
|
66603-10-9
|
Flam. Sol. 1
Acute Tox. 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Chronic 2
|
H228
H301
H373 (lever)
H315
H318
H411
|
GHS02
GHS06
GHS08
GHS05
GHS09
Dgr
|
H228
H301
H373 (lever)
H315
H318
H411
|
|
oral: ATE = 136 mg/kg bw”
|
|
”612-294-00-3
|
N-etyl-N,N-dimetylhexadekan-1-aminiumetylsulfat;
mecetroniumetylsulfat;
[MES]
|
221-106-5
|
3006-10-8
|
Skin Corr. 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H314
H318
H400
H410
|
GHS05
GHS09
Dgr
|
H314
H410
|
EUH071
|
M = 100
M = 1 000 ”
|
|
”613-331-00-6
|
(2RS)-2-[4-(4-klorfenoxi)-2-(trifluormetyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;
mefentriflukonazol
|
–
|
1417782-03-6
|
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H317
H400
H410
|
GHS07
GHS09
Wng
|
H317
H410
|
|
M = 1
M = 1”
|
|
”613-332-00-1
|
oxatiapiprolin (ISO);
1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-tiazol-2-yl}piperidin-1-yl)-2-[5-metyl-3-(trifluormetyl)-1H-pyrazol-1-yl]etanon
|
–
|
1003318-67-9
|
Aquatic Chronic 1
|
H410
|
GHS09
Wng
|
H410
|
|
M = 1”
|
|
”613-333-00-7
|
zinkpyrition; (T-4)-bis[1-(hydroxi-.kappa.O)pyridin-2(1H)-tionato-.kappa.S]zink
|
236-671-3
|
13463-41-7
|
Repr. 1B
Acute Tox. 2
Acute Tox. 3
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H360D
H330
H301
H372
H318
H400
H410
|
GHS08
GHS06
GHS05
GHS09
Dgr
|
H360D
H330
H301
H372
H318
H410
|
|
inhalation: ATE = 0,14 mg/l (damm eller dimma)
oral: ATE = 221 mg/kg bw
M = 1 000
M = 10”
|
|
”613-334-00-2
|
flurokloridon (ISO);
3-klor-4-(klormetyl)-1-[3-(trifluormetyl)fenyl]pyrrolidin-2-on
|
262-661-3
|
61213-25-0
|
Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H360FD
H302
H317
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H360FD
H302
H317
H410
|
|
oral: ATE = 500 mg/kg bw
M = 100
M = 100”
|
|
”613-335-00-8
|
4,5-diklor-2-oktyl-2H-isotiazol-3-on; [DCOIT]
|
264-843-8
|
64359-81-5
|
Acute Tox. 2
Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
|
H330
H302
H314
H318
H317
H400
H410
|
GHS06
GHS05
GHS09
Dgr
|
H330
H302
H314
H317
H410
|
EUH071
|
inhalation: ATE = 0,16 mg/l (damm eller dimma)
oral: ATE = 567 mg/kg bw
Skin Irrit. 2; H315: 0,025 % ≤ C < 5 %
Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100”
|
|
”613-336-00-3
|
2-metyl-1,2-bensotiazol-3-(2H)-on;
[MBIT]
|
–
|
2527-66-4
|
Acute Tox. 4
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 2
|
H312
H301
H314
H318
H317
H400
H411
|
GHS06
GHS05
GHS09
Dgr
|
H312
H301
H314
H317
H410
|
EUH071
|
dermal: ATE = 1 000 mg/kg bw
oral: ATE = 175 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 1”
|
|
”616-228-00-4
|
3-(difluormetyl)-1-metyl-N-(3’,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;
fluxapyroxad
|
–
|
907204-31-3
|
Lact.
Aquatic Acute 1
Aquatic Chronic 1
|
H362
H400
H410
|
GHS09
Wng
|
H362
H410
|
|
M = 1
M = 1”
|
|
”616-230-00-5
|
N-(hydroximetyl)akrylamid; metylolakrylamid; [NMA]
|
213-103-2
|
924-42-5
|
Carc. 1B
Muta. 1B
STOT RE 1
|
H350
H340
H372 (perifera nervsystemet)
|
GHS08
Dgr
|
H350
H340
H372 (perifera nervsystemet)”
|
|
|
|
”616-231-00-0
|
5-fluor-1,3-dimetyl-N-[2-(4-metylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(RS)-1,3-dimetylbutyl]-5-fluor-1,3-dimetylpyrazol-4-karboxanilid;
penflufen
|
–
|
494793-67-8
|
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H400
H410
|
GHS08
GHS09
Wng
|
H351
H410
|
|
M = 1
M = 1”
|
|
”616-232-00-6
|
iprovalikarb (ISO);
isopropyl[(2S)-3-metyl-1-{[1-(4-metylfenyl)etyl]amino}-1-oxobutan-2-yl]karbamat
|
–
|
140923-17-7
|
Carc. 2
|
H351
|
GHS08
Wng
|
H351”
|
|
|
|
”616-233-00-1
|
siltiofam (ISO);
N-allyl-4,5-dimetyl-2-(trimetylsilyl)tiofen-3-karboxamid
|
–
|
175217-20-6
|
STOT RE 2
Aquatic Chronic 2
|
H373
H411
|
GHS08
GHS09
Wng
|
H373
H411”
|
|
|
|
”650-057-00-6
|
margosaextrakt [kallpressad olja av frön utan skal av Azadirachta indica extraherad med superkritisk koldioxid]
|
283-644-7
|
84696-25-3
|
Aquatic Chronic 3
|
H412
|
|
H412”
|
|
|
|